KRAS-targeted therapies in advanced solid cancers: drug the undruggable?

被引：5
|
作者：
Saleh, Khalil [1 ]
Kordahi, Manal [2 ]
Felefly, Tony [3 ]
Kourie, Hampig Raphael [4 ]
Khalife, Nadine [5 ]
机构：
[1] Gustave Roussy Canc Campus, Dept Hematol, F-94800 Villejuif, France
[2] Natl Inst Pathol, Dept Pathol, Baabda 1003, Lebanon
[3] St Joseph Univ, Sch Med, Dept Radiat Oncol, Hotel Dieu France Univ Hosp, Beirut 1100, Lebanon
[4] St Joseph Univ, Fac Med, Dept Hematol Oncol, Beirut 1100, Lebanon
[5] Gustave Roussy Canc Campus, Dept Med Oncol, F-94800 Villejuif, France
来源：
PHARMACOGENOMICS | 2021年 / 22卷 / 10期
关键词：
adagrasib; colorectal cancer; KRAS(G12C) mutations; non-small-cell lung cancer; RAS; sotorasib; KRYSTAL-1; ACTIVITY; ADAGRASIB MRTX849; SAFETY;
D O I：
10.2217/pgs-2021-0045
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
[No abstract available]
引用
收藏
页码：587 / 590
页数：4
相关论文
共 50 条
  • [21] Author Correction: RAS-targeted therapies: is the undruggable drugged?
    Amanda R. Moore
    Scott C. Rosenberg
    Frank McCormick
    Shiva Malek
    Nature Reviews Drug Discovery, 2020, 19 (12) : 902 - 902
  • [22] Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib
    Mausey, Natalie
    Halford, Zachery
    ANNALS OF PHARMACOTHERAPY, 2024, 58 (06) : 622 - 635
  • [23] From bench to bedside: current development and emerging trend of KRAS-targeted therapy
    Yi Chen
    Qiu-pei Liu
    Hua Xie
    Jian Ding
    Acta Pharmacologica Sinica, 2024, 45 : 686 - 703
  • [24] Drug interactions with solid tumour-targeted therapies
    Thomas-Schoemann, Audrey
    Blanchet, Benoit
    Bardin, Christophe
    Noe, Gaelle
    Boudou-Rouquette, Pascaline
    Vidal, Michel
    Goldwasser, Francois
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2014, 89 (01) : 179 - 196
  • [25] Limiting research on molecular targeted therapies in advanced solid cancers: beyond a cost-effectiveness ratio analysis
    Nicolini, Andrea
    Ferrari, Paola
    Carpi, Angelo
    BIOMARKERS IN MEDICINE, 2019, 13 (11) : 887 - 890
  • [26] Targeted therapies in advanced biliary tract cancers-a narrative review
    LaPelusa, Michael
    Heumann, Thatcher
    Goff, Laura
    Agarwal, Rajiv
    CHINESE CLINICAL ONCOLOGY, 2023, 12 (02)
  • [27] Evolving molecularly targeted therapies for advanced-stage thyroid cancers
    Keith C. Bible
    Mabel Ryder
    Nature Reviews Clinical Oncology, 2016, 13 : 403 - 416
  • [28] Evolving molecularly targeted therapies for advanced-stage thyroid cancers
    Bible, Keith C.
    Ryder, Mabel
    NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (07) : 403 - 416
  • [29] Macropinocytic dextran facilitates KRAS-targeted delivery while reducing drug-induced tumor immunity depletion in pancreatic cancer
    Yuan, Fang
    Sun, Mengnan
    Liu, Zhengsheng
    Liu, Huiqin
    Kong, Weijian
    Wang, Rui
    Qian, Feng
    THERANOSTICS, 2022, 12 (01): : 1061 - 1073
  • [30] Review: Side effects of approved molecular targeted therapies in solid cancers
    Widakowich, Christian
    De Castro, Gilberto, Jr.
    De Azambuja, Evandro
    Dinh, Phuong
    Awada, Ahmad
    ONCOLOGIST, 2007, 12 (12): : 1443 - 1455
12345